Updated analysis of induction & maintenance adjuvant chemotherapy with 3-month oxaliplatin-based regimen followed by 3 months capecitabine in patie...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H. Tanioka
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Tanioka1, K. Yamashita2, A. Tsuruta3, A. Tsuji4, T. Nagasaka5, H. Okumura3, Y. Oka3, M. Inukai6, T. Yamakawa7, T. Yamatsuji8, M. Yoshimitsu9, K. Toyota10, T. Yamano11, M. Okajima12
  • 1Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan, /
  • 2Department of Surgery, Okayama Rosai Hospital, Okayama, Japan, /
  • 3Department of Digestive Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan, /
  • 4Department of Medical Oncology, Kagawa University Hospital, Kida-gun, Japan, /
  • 5Department of Digestive Surgery, Okayama University Hospital, Okayama, Japan, /
  • 6Department of Internal Medicine, Okayama Saiseikai Hospital, Okayama, Japan, /
  • 7Department of Surgery, Kagawa Prefectural Central Hospital, Takamatsu, Japan, /
  • 8Department of General Surgery, Kawasaki Medical School, Okayama, Japan, /
  • 9Department of Surgery, Hiroshima City Asa Hospital, Hiroshima, Japan, /
  • 10Department of Surgery, National Hospital Organization Higashihirosima Medical Center, Higashihirosima, Japan, /
  • 11Department of Surgery, Kurashiki Medical Center, Kurashiki, Japan, /
  • 12Department of Surgery, Hiroshima City Hospital, Hiroshima, Japan, /

Abstract

Although 6 months oxaliplatin (OX)-based chemotherapy (modified FOLFOX6 or CAPOX) is one of the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC) in Japan, some cases have irreversible OX induced neurotoxicity. This neuropathy can be reduced by the stop & go strategy of stopping OX after 3 months, without compromising the efficacy. We reported that induction & maintenance adjuvant chemotherapy with a 3-month Ox based regimen followed by 3 months capecitabine was a tolerant feasible regimen and the proportion of grade 3 peripheral sensory neuropathy (PSN) was lower than that previously reported at 6 months of OX-based adjuvant treatments. However, quarter participants in this trial had been suffering from chronic PSN at 6 months follow-up after treatment. In this study, we investigated factors which can predict who has a risk for development of irreversible chronic PSN during OX-based treatments.